-
Baekje Shenzhou: Phase 3 RATIONALE 315 trial of tirelizumab combined with chemotherapy for resectable NSCLC achieved its primary endpoint of MPR and EFS
On October 22nd, the Baekje Shenzhou official announced that the Phase 3 clinical trial of Tirelizumab combined with chemotherapy for resectable NSCLC achieved its primary endpoints of MPR and EFS in ...